Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) · Pancreatic Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) · Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC) · Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma · Triple Negative Breast Cancer (TNBC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
START Midwest, Grand Rapids, Michigan, United States
START San Antonio, San Antonio, Texas, United States
START Mountain Region, West Valley City, Utah, United States
GZA Ziekenhuizen - Campus Sint-Augustinus, Antwerp, Belgium
Clinique Universitaires Saint-Luc, Brussels, Belgium
Contact: Principal Investigator (Rachel Galot)Institute Jules Bordet, Brussels, Belgium
CHU Sart Tilman, Liège, Belgium
Contact: Principal Investigator (Laurence Lousberg)The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Contact: Principal Investigator (Jeff Evans)UCL Hospitals NHS Foundation Trust, London, United Kingdom
Contact: Principal Investigator (Martin Forster)The Christie NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Donna Graham)Newcastle Upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Contact: Principal Investigator (Elizabeth Ruth Plummer)Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Contact: Principal Investigator (Simon Lord)
Study leads
Medical Director
Study Director
Exscientia AI Ltd.